Tapping the potential of DNA delivery with electroporation for cancer immunotherapy

Current Topics in Microbiology and Immunology

Volumn 405, Issue , 2017, Pages 55-78

  Kraynyak, Kimberly A ^a   Bodles Brakhop, Angela ^a   Bagarazzi, Mark ^a  

^a Inovio Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANGIOSTATIN; CABAZITAXEL; CUTANEOUS T CELL ATTRACTING CHEMOKINE; DABRAFENIB; DNA VACCINE; ENDOSTATIN; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 28B; INTERLEUKIN 33; IPILIMUMAB; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SIPULEUCEL T; TOLL LIKE RECEPTOR AGONIST; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB; VPR PROTEIN; WART VIRUS VACCINE; CANCER VACCINE; DNA;

ADJUVANT THERAPY; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CUTANEOUS MELANOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; ELECTROPORATION; GENE GUN; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN PAPILLOMAVIRUS TYPE 16; LONG TERM SURVIVAL; MELANOMA; MELANOMA B16; METASTATIC MELANOMA; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; ADMINISTRATION AND DOSAGE; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PLASMID; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; DNA; ELECTROPORATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PLASMIDS; VACCINES, DNA;

EID: 85024109526     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2015_431     Document Type: Chapter

References (93)

1. Abdulla A, Kapoor A (2011) Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J (Journal de l’Association des urologues du Canada) 5 (2):120-133. doi:10.5489/cuaj.10160
2. Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, Caristi N (2012) Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol 3:73. doi:10.3389/fendo.2012.00073
3. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J (2014) New agents for prostate cancer. Ann Oncol Official J Eur Soc Med Oncol/ESMO 25(9):1700-1709. doi:10.1093/annonc/mdu038
4. Aggarwal P (2014) Cervical cancer: can it be prevented? World J Clin Oncol 5 (4):775-780. doi:10.5306/wjco.v5.i4.775
5. Ahmad S, Casey G, Sweeney P, Tangney M, O’Sullivan GC (2009) Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther: J Am Soc Gene Ther 17(6):1101-1108. doi:10.1038/mt.2009.66
6. Ahmad S, Casey G, Sweeney P, Tangney M, O’Sullivan GC (2010) Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther 8(1):1. doi:10.1186/1479-0556-8-1
7. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, Knott C, Lin F, Boyer JD, Draghia-Akli R, White CJ, Kim JJ, Weiner DB, Sardesai NY (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4(155):155ra138
8. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27(40):5450-5459. doi:10.1016/j.vaccine.2009.07.005
9. Bodles-Brakhop AM, Draghia-Akli R (2008) DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 7(7):1085-1101
10. Bodles-Brakhop AM, Heller R, Draghia-Akli R (2009) Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 17(4):585-592
11. Broderick KE, Chan A, Lin F, Shen X, Kichaev G, Khan AS, Aubin J, Zimmermann TS, Sardesai NY (2012) Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. Mol Ther Nucleic Acids 1:e11. doi:10.1038/mtna.2012.1
12. Broderick KE, Khan AS, Sardesai NY (2014) DNA vaccination in skin enhanced by electroporation. Methods Mol Biol (Clifton, NJ) 1143:123-130. doi:10.1007/978-1-4939-0410-5_8
13. Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J (2005) Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immunol 174 (10):6292-6298
14. Calvet CY, Thalmensi J, Liard C, Pliquet E, Bestetti T, Huet T, Langlade-Demoyen P, Mir LM(2014) Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice. Mol Ther Methods Clin Dev 1. doi:10.1038/mtm.2014.45
15. Chan RC, Gutierrez B, Ichim TE, Lin F (2009) Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma. Oncol Rep 22(5):1197-1203
16. Curcio C, Khan AS, Amici A, Spadaro M, Quaglino E, Cavallo F, Forni G, Draghia-Akli R (2008) DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 15 (2):108-114
17. Denies S, Cicchelero L, Van Audenhove I, Sanders NN (2014) Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release 187:175-182. doi:10.1016/j.jconrel.2014.05.045
18. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA: A Cancer J Clin 64 (4):252-271. doi:10.3322/caac.21235
19. Ferraro B, Cisper NJ, Talbott KT, Philipson-Weiner L, Lucke CE, Khan AS, Sardesai NY, Weiner DB (2011) Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses. Hum Vaccine 7:120-127
20. Ferraro B, Talbott KT, Balakrishnan A, Cisper N, Morrow MP, Hutnick NA, Myles DJ, Shedlock DJ, Obeng-Adjei N, Yan J, Kayatani AK, Richie N, Cabrera W, Shiver R, Khan AS, Brown AS, Yang M, Wille-Reece U, Birkett AJ, Sardesai NY, Weiner DB (2013) Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect Immun 81(10):3709-3720. doi:10.1128/iai.00180-13
21. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB (2013) Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 4:354. doi:10.3389/fimmu.2013.00354
22. Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chursov A, Latanova A, Shcherbinina V, Shifrin V, Shneider A (2014) Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget 5(24):12803-12810
23. Gan L, Jia R, Zhou L, Guo J, Fan M (2014) Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One 9(9):e108892. doi:10.1371/journal.pone.0108892
24. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L (2013) Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther 24(8):728-738. doi:10.1089/hum.2013.112
25. Han KT, Sin JI (2013) DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Clin Exp Vaccine Res 2(2):106-114. doi:10.7774/cevr.2013.2.2.106
26. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R (2000) In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 10(6):577-583
27. Heller LC, Heller R (2010) Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 10(4):312-317
28. Hirao L, Wu L, Khan AS, Hokey D, Yan J, Dai A, Betts M, Draghia-Akli R, Weiner DB (2008) Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 26(25):3112-3120
29. Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, Hammarlund E, Khan AS, Babas T, Rhodes L, Silvera P, Slifka M, Sardesai NY, Weiner DB (2011) Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 203(1):95-102. doi:10.1093/infdis/jiq017
30. Hirao LA, Wu L, Satishchandran A, Khan AS, Draghia-Akli R, Finnefrock AC, Bett AJ, Betts MR, Casimiro DR, Sardesai NY, Kim JJ, Shiver JW, Weiner DB (2010) Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther J Am Soc Gene Ther 18(8):1568-1576. doi:10.1038/mt.2010.112
31. Hutnick NA, Myles DJ, Ferraro B, Lucke C, Lin F, Yan J, Broderick KE, Khan AS, Sardesai NY, Weiner DB (2012) Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum Gene Ther 23(9):943-950. doi:10.1089/hum.2012.055
32. Jacobs JJ, Snackey C, Geldof AA, Characiejus D, Van Moorselaar RJ, Den Otter W (2014) Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus prostate cancer. Anticancer Res 34(6):2689-2700
33. Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, Ganneru B, von Gegerfelt A, Huang W, Guan Y, Broderick KE, Sardesai NY, LaBranche C, Montefiori DC, Pavlakis GN, Felber BK (2012) IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccines Immunotherapeutics 8(11):1620-1629. doi:10.4161/hv.21407
34. Jalah R, Rosati M, Ganneru B, Pilkington GR, Valentin A, Kulkarni V, Bergamaschi C, Chowdhury B, Zhang GM, Beach RK, Alicea C, Broderick KE, Sardesai NY, Pavlakis GN, Felber BK (2013) The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem 288 (9):6763-6776. doi:10.1074/jbc.M112.436675
35. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB (2013) Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 208(5):818-829. doi:10.1093/infdis/jit236
36. Kalat M, Kupcu Z, Schuller S, Zalusky D, Zehetner M, Paster W, Schweighoffer T (2002) In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res 62(19):5489-5494
37. Khan AS, Broderick KE, Sardesai NY (2014) Clinical development of intramuscular electroporation: providing a “boost” for DNA vaccines. Methods in molecular biology (Clifton, NJ) 1121:279-289. doi:10.1007/978-1-4614-9632-8_25
38. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB (1998) Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 17(24):3125-3135. doi:10.1038/sj.onc.1201736
39. Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB (2001a) Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 7(3 Suppl):882s-889s
40. Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB (2001b) Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 20 (33):4497-4506. doi:10.1038/sj.onc.1204542
41. Kraynyak KA, Kutzler MA, Cisper NJ, Khan AS, Draghia-Akli R, Sardesal NY, Lewis MG, Yan J, Weiner DB (2010) Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine 28(8):1942-1951. doi:10.1016/j.vaccine.2009.10.095
42. Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, Zharikova D, Chattergoon M, Maguire H, Muthumani K, Ugen K, Weiner DB (2010) Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Ther 17(1):72-82. doi:10.1038/gt.2009.112
43. Kutzler MA, Weiner DB (2008) DNAvaccines: ready for prime time? Nat Rev Genet 9(10):776-788
44. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25(16):2984-2989
45. Laddy DJ, Yan J, Khan AS, Anderson H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB (2009) Electroporation of synthetic DNA antigens offers protection in non-human primates challenged with highly pathogenic avian influenza. J Virol 83(9):4624-4630
46. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, Draghia-Akli R, Greenhouse J, Sardesai NY, Weiner DB (2008) Induction of heterosubtypic protection against pathogenic human and avian influenza viruses by synthetic consensus DNA antigens. Vaccine 3(6):e2517. doi:10.1371/journal.pone.0002517
47. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB (2008) Strong HCV NS3-and NS4Aspecific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 26(49):6225-6231
48. Latimer B, Toporovski R, Yan J, Pankhong P, Morrow MP, Khan AS, Sardesai NY, Welles SL, Jacobson JM, Weiner DB, Kutzler MA (2014) Strong HCV NS3/4a, NS4b, NS5a, NS5bspecific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/ 1b consensus DNA vaccine. Hum Vaccines Immunotherapeutics 10(8):2357-2365. doi:10.4161/hv.29590
49. Lin F, Shen X, Kichaev G, Mendoza JM, Yang M, Armendi P, Yan J, Kobinger GP, Bello A, Khan AS, Broderick KE, Sardesai NY (2012) Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods 23(3):157-168. doi:10.1089/hgtb.2011.209
50. Lin F, Shen X, McCoy JR, Mendoza JM, Yan J, Kemmerrer SV, Khan AS, Weiner DB, Broderick KE, Sardesai NY (2011) A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29(39):6771-6780. doi:10.1016/j.vaccine.2010.12.057
51. Liu H, Geng S, Feng C, Xie X, Wu B, Chen X, Zou Q, Wang S, Cui J, Xing R, Li W, Lu Y, Wang B (2013) A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model. Hum Vaccines Immunotherapeutics 9(10):2196-2202. doi:10.4161/hv.25013
52. Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, Kiessling R (2010) Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother CII 59(1):81-92. doi:10.1007/s00262-009-0725-4
53. Lollini PL, Cavallo F, De Giovanni C, Nanni P (2013) Preclinical vaccines against mammary carcinoma. Expert Rev Vaccines 12(12):1449-1463. doi:10.1586/14760584.2013.845530
54. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH (2009) DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 20(11):1269-1278
55. Mao L, Sun W, Li W, Cui J, Zhang J, Xing R, Lu Y (2014) Cell cycle-dependent expression of p42.3 promotes mitotic progression in malignant transformed cells. Mol Carcinogenesis 53 (5):337-348. doi:10.1002/mc.21982
56. Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11(8):781-789. doi:10.1016/s1470-2045(10)70017-6
57. McCray AN, Ugen KE, Heller R (2007) Enhancement of anti-melanoma activity of a plasmid expressing HIV-1Vpr delivered through in vivo electroporation. Cancer Biol Ther 6(8):1269-1275
58. McCray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB, Heller R (2006) Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vprexpressing plasmid by in vivo electroporation. Mol Ther 14(5):647-655
59. Morrow MP, Yan J, Pankhong P, Ferraro B, Lewis MG, Khan AS, Sardesai NY, Weiner DB (2010) Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol CVI 17(10):1493-1499. doi:10.1128/cvi.00181-10
60. Morrow MP, Yan J, Sardesai NY (2013) Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines 12 (3):271-283. doi:10.1586/erv.13.23
61. Muthumani K, Lambert VM, Kawalekar O, Heller R, Kim JJ, Weiner DB, Ugen KE (2010) Anticancer activity of the HIV accessory molecule viral protein R (Vpr): Delivery as a DNA expression plasmid or biologically active peptides. Vaccine 28(8):2005-2010. doi:10.1016/j.vaccine.2009.10.060
62. Muthumani K, Lambert VM, Shanmugam M, Thieu KP, Choo AY, Chung JC, Satishchandran A, Kim JJ, Weiner DB, Ugen KE (2009) Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther 8(2):180-187
63. Muthumani K, Wise MC, Broderick KE, Hutnick N, Goodman J, Flingai S, Yan J, Bian CB, Mendoza J, Tingey C, Wilson C, Wojtak K, Sardesai NY, Weiner DB (2013) HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B-and T-cell responses and neutralizing phenotype in vivo. PLoS One 8(12):e84234. doi:10.1371/journal.pone.0084234
64. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R (2010) Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 8:53. doi:10.1186/1479-5876-8-53
65. Ohlschlager P, Quetting M, Alvarez G, Durst M, Gissmann L, Kaufmann AM (2009) Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by coapplication of sequence-optimized genetic adjuvants. Int J Cancer 125(1):189-198
66. Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M (2011) The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer J Int du Cancer 128(2):473-481. doi:10.1002/ijc.25344
67. Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L (2010) A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther J Am Soc Gene Ther 18(8):1559-1567. doi:10.1038/mt.2010.104
68. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di CE, Pupa SM, De GC, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 64(8):2858-2864
69. Radkevich-Brown O, Piechocki MP, Back JB, Weise AM, Pilon-Thomas S, Wei WZ (2010) Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression. Cancer Immunol Immunother CII 59(3):409-417. doi:10.1007/s00262-009-0760-1
70. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95(4):1735-1740
71. Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F (2014) CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res Official J Am Assoc Cancer Res 20(14):3753-3762. doi:10.1158/1078-0432.ccr-13-3042
72. Roos AK, Eriksson F, Walters DC, Pisa P, King AD (2009) Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther 17(9):1637-1642
73. Roos AK, King A, Pisa P (2008) DNA vaccination for prostate cancer. In: Li S (ed) Methods in molecular biology. Electroporation protocols. Preclinical and clinical gene medicine, vol 423. Humana Press, Totowa, New Jersey, 07512, pp 463-472
74. Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P (2006) Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 13(2):320-327
75. Sajadian A, Tabarraei A, Soleimanjahi H, Fotouhi F, Gorji A, Ghaemi A (2014) Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol 159(8):1951-1960. doi:10.1007/s00705-014-2024-4
76. Saranga-Perry V, Ambe C, Zager JS, Kudchadkar RR (2014) Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin 64(3):171-185. doi:10.3322/caac.21224
77. Sardesai NY, Weiner DB (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23(3):421-429
78. Seo SH, Jin HT, Park SH, Youn JI, Sung YC (2009) Optimal induction of HPV DNA vaccineinduced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 27(42):5906-5912. doi:10.1016/j.vaccine.2009.07.033
79. Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, Villarreal DO, Myles DJ, Croyle MA, Yan J, Kobinger GP, Weiner DB (2013) Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther J Am Soc Gene Ther 21(7):1432-1444. doi:10.1038/mt.2013.61
80. Shin TH, Pankhong P, Yan J, Khan AS, Sardesai NY, Weiner DB (2012) Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen. Hum Vaccines Immunotherapeutics 8(4):470-478. doi:10.4161/hv.19180
81. Smorlesi A, Papalini F, Amici A, Orlando F, Pierpaoli S, Mancini C, Provinciali M (2006) Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24(11):1766-1775
82. Spies E, Reichardt W, Alvarez G, Groettrup M, Ohlschlager P (2012) An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Mol Ther J Am Soc Gene Ther 20(3):555-564. doi:10.1038/mt.2011.241
83. Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, Ishii N, Suzuki K, Klinman DM, Okuda K, Sasaki S (2006) Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 80(13):6218-6224. doi:10.1128/jvi.00121-06
84. Venanzi F, Shifrin V, Sherman M, Gabai V, Kiselev O, Komissarov A, Grudinin M, Shartukova M, Romanovskaya-Romanko EA, Kudryavets Y, Bezdenezhnykh N, Lykhova O, Semesyuk N, Concetti A, Tsyb A, Filimonova M, Makarchuk V, Yakubovsky R, Chursov A, Shcherbinina V, Shneider A (2013) Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget 4(10):1829-1835
85. Villarreal DO, Talbott KT, Choo DK, Shedlock DJ, Weiner DB (2013) Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines 12(5):537-554. doi:10.1586/erv.13.33
86. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB (2014) Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 74(6):1789-1800. doi:10.1158/0008-5472.can-13-2729
87. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1):1465-1468
88. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell DA, Weiner DB (2008) Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 26(40):5210-5215
89. Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY, Weiner DB (2013) Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res 1(3):179-189. doi:10.1158/2326-6066.cir-13-0001
90. Yan J, Tingey C, Lyde R, Gorham TC, Choo DK, Muthumani A, Myles D, Weiner LP, Kraynyak KA, Reuschel EL, Finkel TH, Kim JJ, Sardesai NY, Ugen KE, Muthumani K, Weiner DB (2014a) Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Ther. doi:10.1038/cgt.2014.56
91. Yan J, Villarreal DO, Racine T, Chu JS, Walters JN, Morrow MP, Khan AS, Sardesai NY, Kim JJ, Kobinger GP, Weiner DB (2014b) Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine 32(24):2833-2842. doi:10.1016/j.vaccine.2014.02.038
92. Yersal O, Barutca S (2014) Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol 5(3):412-424. doi:10.5306/wjco.v5.i3.412
93. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol (Baltimore, Md: 1950) 176 (12):7335-7345